Zacks Research Expects Weaker Earnings for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Equities researchers at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for Kodiak Sciences in a research report issued on Wednesday, June 4th. Zacks Research analyst R. Department now expects that the company will post earnings per share of ($1.02) for the quarter, down from their prior forecast of ($0.94). The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. Zacks Research also issued estimates for Kodiak Sciences' Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($4.08) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.88) EPS, FY2026 earnings at ($3.65) EPS, Q1 2027 earnings at ($0.76) EPS and FY2027 earnings at ($2.87) EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.20).

Separately, HC Wainwright reaffirmed a "neutral" rating and issued a $3.00 price objective on shares of Kodiak Sciences in a report on Monday, March 31st.

Kodiak Sciences Price Performance

KOD traded up $0.30 during trading on Friday, hitting $4.22. The stock had a trading volume of 354,244 shares, compared to its average volume of 347,375. The company has a 50 day moving average price of $3.42 and a 200-day moving average price of $5.37. The firm has a market cap of $222.66 million, a price-to-earnings ratio of -1.16 and a beta of 2.27. Kodiak Sciences has a one year low of $1.92 and a one year high of $11.60.

Hedge Funds Weigh In On Kodiak Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KOD. SG Americas Securities LLC raised its holdings in Kodiak Sciences by 61.4% in the 4th quarter. SG Americas Securities LLC now owns 20,684 shares of the company's stock valued at $206,000 after acquiring an additional 7,871 shares in the last quarter. Peapod Lane Capital LLC acquired a new position in shares of Kodiak Sciences during the 4th quarter worth $1,660,000. Bank of New York Mellon Corp raised its holdings in shares of Kodiak Sciences by 5.3% during the 4th quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company's stock worth $976,000 after buying an additional 4,927 shares in the last quarter. US Bancorp DE acquired a new position in shares of Kodiak Sciences during the 4th quarter worth $40,000. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Kodiak Sciences by 1,501.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock worth $32,000 after buying an additional 2,988 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.